The new Phenomics Core of the Scripps NeuroAIDS Preclinical Studies (SNAPS) Center will provide SNAPS investigators and others with cutting-edge analytical support and data access, to address the primary challenges in metabolite and protein profiling, and functional genomics. Identification, quantification, and correlation of the broad range of metabolites and proteins with biochemical and transcriptional events relevant to neuroAIDS and the central nervous system. Meeting this challenge is integral to understanding the progression of disease and the development of diagnostic and treatment tools. Applying state-of-thescience approaches in high density gene expression arrays, global metabolite profiling and comparative proteomic analysis will permit the identification of specific metabolites and proteins associated with neurodegenerative processes and facilitate a deeper understanding of basic problems in neuroAIDS. Affymetrix GeneChip expression arrays and custom array technology will be provided that would otherwise be unavailable or prohibitively expensive. A key component of the Phenomics Core support will be the expansion of bioinformatics and statistics resources through active collaboration with the proposed Systems Biology and Integrative Network Core and the Statistics section of the Administrative Core. This collaborative effort will result in data collection, sharing and analysis capabilities that are simultaneously diverse and integrated, generating a unique resource for neuroAIDS research. The Core will continue providing training and assistance with bioinformatics tools for microarray data analysis, protein-ligand interactions, metabolomics and proteomics, and the management and dissemination of datasets. The ultimate goal of the Prvenomics Core is to provide analytical support in the design and implementation of cutting edge transcriptomics, metabolomics and proteomics focused upon the pathoneurological effects of HIV/AIDS.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Guijas, Carlos; Montenegro-Burke, J Rafael; Warth, Benedikt et al. (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36:316-320
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40
Dave, Rajnish S; Jain, Pooja; Byrareddy, Siddappa N (2018) Functional Meningeal Lymphatics and Cerebrospinal Fluid Outflow. J Neuroimmune Pharmacol 13:123-125
Dyavar, Shetty Ravi; Ye, Zhen; Byrareddy, Siddappa N et al. (2018) Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. Sci Rep 8:3626
Ottemann, Brendan M; Helmink, Austin J; Zhang, Wenting et al. (2018) Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 185:174-193
Brenza, Timothy M; Schlichtmann, Benjamin W; Bhargavan, Biju et al. (2018) Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. J Biomed Mater Res A 106:2881-2890
Sathyanesan, Monica; Watt, Michael J; Haiar, Jacob M et al. (2018) Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry 8:113
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65

Showing the most recent 10 out of 374 publications